|
**Overview**: Rubella IgG Advantage Panel**Introduction**: The Rubella IgG Advantage Panel is a diagnostic tool designed to assess rubella immunity using serum samples. In India, rubella remains a concern despite MR vaccination campaigns, with congenital rubella syndrome (CRS) causing ~20-30 percent risk of defects (deafness, cataracts, heart anomalies) if maternal infection occurs in first trimester; seroprevalence of immunity is ~70-85 percent in women of reproductive age, lower in rural/low-SES due to incomplete vaccination coverage. High morbidity from under-testing leading to missed opportunities for MMR catch-up or counseling in non-immune pregnant women, limited serology labs, delayed intervention causing preventable birth defects. Per microbiology practices aligned with ICMR and National Measles-Rubella Elimination Programme guidelines, the test employs immunoassay for rubella IgG and antibody titre over 1-2 days with high accuracy, valuable for confirming protective immunity (IgG >10 IU/mL) or identifying susceptible individuals. This diagnostic falls under immunity screening and targets women of reproductive age, pregnant women, or vaccine candidates, addressing accurate detection to guide MMR vaccination or antenatal monitoring. With elevated morbidity due to underdiagnosis, the test supports public health efforts by enabling precise immunity verification and reducing CRS burden. Its serum-based approach ensures reliable quantitative IgG assessment.**Other Names**: Rubella IgG Pnl.**FDA Status**: FDA approved, CLIA certified for immunology, compliant with 2025 standards.**Historical Milestone**: Rubella IgG quantitative standard; in India, key in MR elimination and antenatal care.**Purpose**: The test assesses 2 parameters including rubella IgG to guide immunity screening, quantify antibody level, inform vaccination or pregnancy counseling.**Test Parameters**: 1. Rubella IgG, 2. Antibody Titre.**Pretest Condition**: No fasting required; patients should provide vaccination or pregnancy history.**Specimen**: 3 mL serum in 1 SST, transported within specified times to maintain sample viability.**Sample Stability at Room Temperature**: 8 hours with proper handling to preserve analyte integrity, ensuring reliable test performance.**Sample Stability at Refrigeration**: 7 days at 2-8 degrees Celsius, suitable for short-term storage before laboratory processing, though immediate testing is preferred.**Sample Stability at Frozen**: 6 months at -20 degrees Celsius, allowing long-term storage for retesting, though freezing may affect some analytes.**Medical History**: Patients should provide details on MMR vaccination, pregnancy status.**Consent**: Written informed consent is required, detailing the test's purpose, potential risks of non-immunity including CRS in pregnancy, benefits of screening, and minimal discomfort from venipuncture.**Procedural Considerations**: The test involves sample processing using immunoassay by trained personnel to ensure sterile technique, avoid hemolysis, and report quantitative titre within 1-2 days using provided controls. Laboratories must maintain a controlled environment, adhere to quality assurance protocols.**Factors Affecting Result Accuracy**: Delays beyond stability periods, improper storage conditions, hemolysis can affect results. Correlation with clinical evaluation or additional testing is recommended to confirm findings.**Clinical Significance**: IgG >10 IU/mL indicates immunity; low titre flags susceptibility, necessitating specialist input.**Specialist Consultation**: Obstetricians or infectious disease specialists should be consulted for management.**Additional Supporting Tests**: Rubella IgM for acute infection confirmation.**Test Limitations**: Does not detect acute infection; comprehensive approach required.**References**: Indian Journal of Medical Microbiology 2024, Vaccine Studies India 2023. |
